[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Scar Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

August 2019 | 70 pages | ID: G5A5F7EB67CEN
VPAResearch

US$ 1,799.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
High levels of pipeline activity are being observed in Scar treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including Abzena Plc, BirchBioMed Inc, Cotinga Pharmaceuticals Inc, Ember Therapeutics Inc, FBM Therapeutics LLC and others.

A Significant contribution to the Scar pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Scar pipeline included 16 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Scar condition and increased access to investments is encouraging growth of Scar drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Scar drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Scar therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Scar pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Scar. Further, orphan drug status, fast track designation, grants awarded and other special status for Scar pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Scar pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Scar Pipeline candidates-
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Scar drugs
  • Late phase: Phase 3 and in-approval Scar drugs
Companies involved in the Pipeline-
  • Company overview
  • Snapshot
  • Scar therapeutic treatment activities
Details for each Scar drug candidate-
  • Snapshot
    • Drug Name
    • Alternative Names
    • Company
    • Originator
    • Phase
    • Molecule Type
    • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Scar therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 EXECUTIVE SUMMARY

2.1 Scar- Disease Overview
2.2 Scar- Pipeline Snapshot
2.3 Scar- Pipeline Drugs by Phase
2.4 Scar- Pipeline Drugs by Company
2.5 Scar- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

3.1 Abzena Plc Scar Drug Pipeline, H2- 2019
3.2 BirchBioMed Inc Scar Drug Pipeline, H2- 2019
3.3 Cotinga Pharmaceuticals Inc Scar Drug Pipeline, H2- 2019
3.4 Ember Therapeutics Inc Scar Drug Pipeline, H2- 2019
3.5 FBM Therapeutics LLC Scar Drug Pipeline, H2- 2019
3.6 Kringle Pharma Inc Scar Drug Pipeline, H2- 2019
3.7 Moerae Matrix Inc Scar Drug Pipeline, H2- 2019
3.8 Pharmaxis Ltd Scar Drug Pipeline, H2- 2019
3.9 Phio Pharmaceuticals Corp Scar Drug Pipeline, H2- 2019
3.10 Promore Pharma AB Scar Drug Pipeline, H2- 2019
3.11 Resolys Bio Inc Scar Drug Pipeline, H2- 2019
3.12 Scarless Laboratories Inc Scar Drug Pipeline, H2- 2019
3.13 ScarX Therapeutics Scar Drug Pipeline, H2- 2019
3.14 Synedgen Inc Scar Drug Pipeline, H2- 2019
3.15 Temple Therapeutics BV Scar Drug Pipeline, H2- 2019
3.16 Vascular BioSciences Scar Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

4.1 Scar- Phase 1 Drug Details
4.2 Scar- Phase 1 Drug Overview
4.3 Scar- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

5.1 Scar- Phase 2 Drug Details
5.2 Scar- Phase 2 Drug Overview
5.3 Scar- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 PHASE 3 PIPELINE DRUG DETAILS

6.1 Scar- Phase 3 Drug Details
6.2 Scar- Phase 3 Drug Overview
6.3 Scar- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

7.1 Scar- Pre-clinical Phase Drug Details
7.2 Scar- Pre-clinical Phase Drug Overview
7.3 Scar- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

9.1 About VPAResearch
9.2 Sources and Research Methodology


More Publications